Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity

Pharmacogenetics

Volumn 10, Issue 8, 2000, Pages 705-713

  Pirmohamed, M ^a   Alfirevic, A ^a   Vilar, J ^a   Stalford, A ^a   Wilkins, E G L ^a   Sim, E ^a   Park, B K ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Co trimoxazole; Hypersensitivity; Polymorphisms; Sulphonamide

Indexed keywords

COTRIMOXAZOLE; HYDROXYLAMINE; SULFAMETHOXAZOLE; SULFONAMIDE; TAQ POLYMERASE;

ACETYLATOR PHENOTYPE; ARTICLE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DRUG HYPERSENSITIVITY; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ACETYLATION; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ARYLAMINE N-ACETYLTRANSFERASE; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; GENOTYPE; GLUTATHIONE TRANSFERASE; HIV SEROPOSITIVITY; HUMANS; HYPERSENSITIVITY; METABOLIC DETOXICATION, DRUG; ODDS RATIO; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; SULFAMETHOXAZOLE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0033656847     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200011000-00005     Document Type: Article

References (56)

1. Co-trimoxazole use restricted
2. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15 438 consecutive inpatients, 1975 to 1982
3. Correlation between genotype and phenotype of the human arylamine N- acetyltransferase type 1 (NAT1)
4. Pathogenesis and management of HIV-associated drug hypersensitivity
5. Efficacy and safety of rechallenge with low-dose trimethoprim sulfamethoxazole in previously hypersensitive HIV-infected patients
6. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV
7. Acetylation phenotype and cutaneous hypersensitivity to trimethoprimsulphamethoxazole in HIV-infected patients
8. Evolving pattern of drug-induced toxic epidermal necrolysis
9. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione: Implications for idiosyncratic toxicity
10. Role of polymorphic and monomorphic human arylamine n-acetyltransferases in determining sulfamethoxazole metabolism
11. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes
12. N-acetylation genotype and risk of severe reactions to sulfonamides in AIDS patients
13. Glutathione S-transferase (GSTM1) null genotype and sulphonamide intolerance in acquired immunodeficiency syndrome
14. No association between tacrine transaminitis and the glutathione transferase theta genotype in patients with Alzheimer's disease
15. The association of the slow acetylator phenotype with bladder cancer
16. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
17. The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole
18. The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat
19. The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation
20. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome
21. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer
22. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk
23. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans
24. Genotyping human polymorphic arylamine N-acetyltransferase: Identification of new slow allotypic variants
25. Complications of co-trimoxazole in treatment of AIDS-associated pneumocystis carinii pneumonia in homosexual men
26. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus
27. cDNA and amino acid sequences of two members of the human P450IIC gene subfamily
28. Adverse reactions to sulfosoxazole, sulfamethoxazole, and nitrofurantoin. Manifestations and specific reaction rates during 2118 courses of therapy
29. Altered patterns of drug-metabolism in patients with acquired-immunodeficiency-syndrome
30. Synthesis and reactions of nitroso sulfamethoxazole with biological nucleophiles - Implications for immune-mediated toxicity
31. Cellular disposition of sulphamethoxazole and its metabolites: Implications for hypersensitivity
32. N-acetylation among HIV-positive patients and patients with AIDS: When is fast, fast and slow, slow?
33. The role of drug disposition in drug hypersensitivity: A chemical, molecular and clinical perspective
34. Human glutathione-S-transferase-theta (GSTT1) - cDNA cloning and the characterization of a genetic-polymorphism
35. The role of active metabolites in drug toxicity
36. Idiosyncratic drug reactions: Metabolic bioactivation as a pathogenic mechanism
37. Adverse drug reactions
38. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
39. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro 'rechallenge' with hydroxylamine metabolites
40. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions
41. Glutathione transferase μ deficiency is not a marker for predisposition to sulphonamide toxicity
42. Drug-induced toxic epidermal necrolysis (lyell syndrome) in patients infected with the human-immunodeficiency-virus
43. Efficacy and toxicity of 2 doses of trimethoprim-sulfamethoxazole as primary prophylaxis against pneumocystis-carinii pneumonia in patients with human-immunodeficiency-virus
44. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alpha/beta T cell clones
45. Hereditary interindividual differences in the glutathione transferase activity towards trans-stilbene oxide in resting human mononuclear leukocytes are due to a particular isozyme(s)
46. Genetic analysis of the human cytochrome P450 CYP2C9 locus
47. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
48. Formation and elimination of sulfamethoxazole hydroxylamine after oral-administration of sulfamethoxazole
49. Drug intolerance in HIV disease
50. Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV-seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole
51. Nomenclature for N-acetyltransferases
52. Tolbutamide hydroxylation in humans: Lack of bimodality in 106 healthy subjects
53. Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human alpha beta (+) T cell clones
54. Isolation, identification and determination of sulfamethoxazole and its known metabolites in human plasma and urine by high-performance liquid-chromatography
55. A slow acetylator genotype is a risk factor for sulfonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome
56. The arylamine N-acetyltransferase (NAT2) polymorphism and the risk of adverse reactions to co-trimoxazole in children